These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37944195)

  • 21. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
    Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients.
    Sharma K; Chaudhary D; Beard K; Srivastava S; Khalid SH; Sriwastava S
    Mult Scler Relat Disord; 2022 Mar; 59():103675. PubMed ID: 35168095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicians' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A; Whichello C; Le HH; Kern DM; Fernandez GS; Turner V; Das A; Quaife M; Ross AP
    Pharmacoecon Open; 2024 Nov; 8(6):857-867. PubMed ID: 39196477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
    Montgomery SM; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia.
    Lasalvia P; Hernández F; Castañeda-Cardona C; Cuestas JA; Rosselli D
    Value Health Reg Issues; 2020 Dec; 23():13-18. PubMed ID: 31999987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis.
    Volpi C; Orabona C; Macchiarulo A; Bianchi R; Puccetti P; Grohmann U
    Expert Opin Drug Discov; 2019 Nov; 14(11):1199-1212. PubMed ID: 31389262
    [No Abstract]   [Full Text] [Related]  

  • 29. Oxidative stress activity of fingolimod in multiple sclerosis.
    Yevgi R; Demir R
    Clin Neurol Neurosurg; 2021 Mar; 202():106500. PubMed ID: 33508648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.
    Fronza M; Lorefice L; Frau J; Cocco E
    Drug Des Devel Ther; 2021; 15():1993-2004. PubMed ID: 34007159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.
    Rezaee M; Izadi S; Keshavarz K; Borhanihaghighi A; Ravangard R
    J Med Econ; 2019 Apr; 22(4):297-305. PubMed ID: 30561242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
    Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
    CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
    Poveda JL; Trillo JL; Rubio-Terrés C; Rubio-Rodríguez D; Polanco A; Torres C
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):295-303. PubMed ID: 31220959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P
    Kihara Y; Jonnalagadda D; Zhu Y; Ray M; Ngo T; Palmer C; Rivera R; Chun J
    FASEB J; 2022 Feb; 36(2):e22132. PubMed ID: 34986275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
    Spelman T; Herring WL; Zhang Y; Tempest M; Pearson I; Freudensprung U; Acosta C; Dort T; Hyde R; Havrdova E; Horakova D; Trojano M; De Luca G; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Alroughani R; Pucci E; Granella F; Lechner-Scott J; Sola P; Ferraro D; Grand'Maison F; Terzi M; Rozsa C; Boz C; Hupperts R; Van Pesch V; Oreja-Guevara C; van der Walt A; Jokubaitis VG; Kalincik T; Butzkueven H;
    Pharmacoeconomics; 2022 Mar; 40(3):323-339. PubMed ID: 34921350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK.
    Montgomery SM; Maruszczak MJ; Slater D; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 May; 20(5):474-482. PubMed ID: 28008769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada.
    Nakhaipour HR; Vudumula U; Khurana V; Sébire G; Mah JK; Pohl D; Schecter R; Adlard N
    J Med Econ; 2020 Dec; 23(12):1525-1533. PubMed ID: 33079578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.